特一药业 (002728.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	839.3M	924.5M	687.8M	1.1B	886.6M
Cost of Revenue	397.3M	419.5M	385.7M	468.0M	451.8M
Gross Profit	442.0M	505.0M	302.1M	599.2M	434.7M
Operating Expenses
R&D Expense	44.1M	44.4M	43.3M	43.1M	38.0M
SG&A Expense	—	—	—	—	—
General & Admin Expense	74.9M	72.3M	74.4M	66.3M	59.0M
Selling & Marketing Expense	242.4M	299.2M	151.1M	174.4M	117.4M
Other Expenses	—	—	—	—	—
Total Operating Expenses	374.0M	431.6M	276.2M	300.8M	245.6M
Cost and Expenses	771.3M	851.1M	662.0M	768.8M	697.5M
Operating Income (EBIT)	76.9M	81.2M	24.1M	293.3M	196.5M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	78.0M	82.3M	22.1M	293.0M	196.3M
Income Tax Expense	2.1M	613.3K	1.6M	39.8M	18.1M
Bottom Line
Net Income	75.9M	81.7M	20.5M	253.2M	178.2M
Earnings from Cont. Ops	75.9M	81.7M	20.5M	253.2M	178.2M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	75.9M	81.7M	20.5M	253.2M	178.2M
Per Share
Basic EPS	CN¥0.15	CN¥0.16	CN¥0.04	CN¥0.55	CN¥0.57
Diluted EPS	CN¥0.15	CN¥0.16	CN¥0.04	CN¥0.55	CN¥0.57
Revenue Per Share	CN¥1.63	CN¥1.81	CN¥1.34	CN¥2.32	CN¥2.84
Shares
Basic Shares Outstanding	515.3M	510.4M	512.4M	460.3M	312.6M
Diluted Shares Outstanding	515.3M	510.4M	512.4M	460.3M	312.6M
Profitability Metrics
EBITDA	—	151.0M	88.5M	353.4M	249.1M
D&A	—	69.8M	64.4M	60.2M	52.6M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026